Am-Ka12K4
Am-Ka12K4 is a weakly positively charged peptide-based ionizable lipid. Am-Ka12K4 induces membrane disruption under endosomal pH conditions and possesses high lipid fusion capacity. Am-Ka12K4 forms tightly packed, stable lipid nanoparticles. Am-Ka12K4 mediates in vivo mRNA delivery, exhibits inherent liver tropism, and can be modified to adjust organ tropism, enabling selective mRNA delivery to the spleen, lung, or thymus. Am-Ka12K4 is applicable to research related to repetitive mild traumatic brain injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3113145-60-8
- Formule: C126H255N11O5
- Masse moléculaire:2004.44
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Am-Ka12K4 LNPs (total RNA dose of 4 mg/kg; intravenous injection; once every 2 days; 3 doses total) mediate lung tissue-specific prime editing in EGFP reporter mice, with an efficiency of 7.4%[1].
Am-Ka12K4 (INBT) LNP (1.0 mg/kg; intranasal administration; intravenous injection; single dose) efficiently delivers mRNA to the injured brain regions of rmTBI mice via olfactory and trigeminal nerve pathways, transfects microglia, astrocytes and neurons with high brain region specificity, and shows minimal off-target distribution in the periphery[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ai9 reporter mice (female, C57BL/6 background, 6-8 weeks old, 18-20 g)[1]
-
Dosage:Lipid molar ratio of Am-Ka12K4/DSPC/cholesterol/PEG-DMG = 46.3:9.4:42.7:1.6
-
Administration:i.v.; single dose
-
Result:Achieved 27.8-fold higher tdTomato expression in the lungs compared with the PBS group, with negligible off-target editing in other organs.
Confirmed lung-specific gene editing in epithelial, endothelial, and immune cells via flow cytometry.
-
Animal Model:EGFP reporter mice (female, C57BL/6 background, 6-8 weeks old, 18-20 g)[1]
-
Dosage:4 mg/kg total RNA
-
Administration:i.v.; once every 2 days; 3 total doses
-
Result:Mediated a T-to-C point correction prime editing efficiency of 7.4% in the lungs.
Showed widespread EGFP-positive cells via immunofluorescence.
-
Animal Model:C57BL/6J mice (repetitive mild traumatic brain injury induced)[2]
-
Dosage:1.0 mg/kg
-
Administration:i.n.; single dose; i.v.; single dose
-
Result:Resulted in significantly higher total radiant efficiency in the brain (P = 0.0002), nasal cavity (P = 0.0427), trigeminal nerves (P = 0.0242), and olfactory bulb (P = 0.0143) compared to PBS controls.
Produced significantly higher brain mCherry expression than intravenous INBT LNP or intravenous SM-102 LNP controls.
Detected mCherry fluorescence in microglia (Iba1+), astrocytes (GFAP+), and neurons (NeuN+) in the ipsilateral cortex and hippocampus, with preferential transfection in the injured brain hemisphere.
Showed minimal off-target fluorescence in peripheral organs following intranasal administration.
Chemical Information
-
CAS No. 3113145-60-8
-
Masse moléculaire 2004.44
-
Formule C126H255N11O5
-
SMILES
CCCCCCCCCCCCN(CCCC[C@H](NC([C@H](CCCCN)N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC)=O)CCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC)=O)CCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC)=O)CCCCCCCCCCCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Lin Y, et al. Tissue-specific mRNA delivery and prime editing with peptide-ionizable lipid nanoparticles. Nature materials. 2026 Jan;25(1):133-145. [Content Brief]
[2]. Yu X, et al. Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood-Brain Barrier for Effective Brain Disease Therapy. ACS nano. 2026 Jun 02;20(21):15589-15605. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Am-Ka12K4 Related Classifications
HY-185985 Related Classifications
Powered by Bioz